drugset / Trial / NCT02817945

Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging

NCT02817945 ↗

Phase 0 Unknown 100 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluate the efficacy of 68Ga-NOTA-3PTATE-RGD in lung cancer patients and neuroendocrine neoplam patients. A single dose of 111-185 Mega-Becquerel (MBq) 68Ga-NOTA-3P-TATE-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Timeline

Start
2016-06-01
Primary completion
2020-12-01
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-NOTA-3P-TATE-RGD Peptide 111 mbq Intravenous
Subject 68Ga-NOTA-3P-TATE-RGD Peptide 185 mbq Intravenous